Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L, Kraus M, Besse A, Driessen C, Tarantino I. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma. Sci Rep 2023; 13:4411.
17.03.2023The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
17.03.2023Sci Rep 2023; 13:4411
Besse Lenka, Kraus Marianne, Besse Andrej, Driessen Christoph, Tarantino Ignazio
Acupuncture in chemotherapy-induced dysgeusia (AcuDysg): study protocol of a randomised controlled trial.
Huber C, Zhang L, Schlaeppi M, Müller T, Roll S, Voiss P, Barth J, Driessen C, Witt C. Acupuncture in chemotherapy-induced dysgeusia (AcuDysg): study protocol of a randomised controlled trial. BMJ Open 2023; 13:e066137.
10.03.2023Acupuncture in chemotherapy-induced dysgeusia (AcuDysg): study protocol of a randomised controlled trial.
10.03.2023BMJ Open 2023; 13:e066137
Huber Christine, Zhang Linxin, Schlaeppi Marc, Müller Twyla, Roll Stephanie, Voiss Petra, Barth Jürgen, Driessen Christoph, Witt Claudia M
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Joerger M, Hundsberger T, Haefliger S, von Moos R, Hottinger A, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Invest New Drugs 2023
16.02.2023Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
16.02.2023Invest New Drugs 2023
Joerger Markus, Hundsberger Thomas, Haefliger Simon, von Moos Roger, Hottinger Andreas F, Kaindl Thomas, Engelhardt Marc, Marszewska Michalina, Lane Heidi, Roth Patrick, Stathis Anastasios
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Çakar E, Oniangue-Ndza C, Schneider R, Klijn S, Vogl U, Rothermundt C, May J. Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. Pharmacoecon Open 2023
09.02.2023Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
09.02.2023Pharmacoecon Open 2023
Çakar Esra, Oniangue-Ndza César, Schneider Ralph P, Klijn Sven L, Vogl Ursula M, Rothermundt Christian, May Jessica R
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz M, Shimizu C, Huang C, Lueck H, Beith J, Tokunaga E, Contreras J, de Sant'Ana R, Wei R, Shahir A, Nabinger S, Forrester T, Johnston S, Harbeck N. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer. Ther Adv Med Oncol 2023; 15:17588359231151840.
03.02.2023Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
03.02.2023Ther Adv Med Oncol 2023; 15:17588359231151840
Paluch-Shimon Shani, Neven Patrick, Huober Jens, Cicin Irfan, Goetz Matthew P, Shimizu Chikako, Huang Chiun-Sheng, Lueck Hans Joachim, Beith Jane, Tokunaga Eriko, Contreras Jessica Reyes, de Sant'Ana Rosane Oliveira, Wei Ran, Shahir Ashwin, Nabinger Sarah C, Forrester Tammy, Johnston Stephen R D, Harbeck Nadia
High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Zhou X, Besse A, Peter J, Steinhardt M, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Xiao X, Hornburger H, Haertle L, Lopez M, Munawar U, Riedel A, Han S, Maurits E, Overkleeft H, Florea B, Einsele H, Kortüm K, Driessen C, Besse L, Rasche L. High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex. Haematologica 2023
02.02.2023High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
02.02.2023Haematologica 2023
Zhou Xiang, Besse Andrej, Peter Jessica, Steinhardt Maximilian Johannes, Vogt Cornelia, Nerreter Silvia, Teufel Eva, Stanojkovska Emilia, Xiao Xianghui, Hornburger Hannah, Haertle Larissa, Lopez Max Mendez, Munawar Umair, Riedel Angela, Han Seungbin, Maurits Elmer, Overkleeft Herman S, Florea Bogdan, Einsele Hermann, Kortüm K Martin, Driessen Christoph, Besse Lenka, Rasche Leo
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
Di Cosimo S, Ciniselli C, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez H, Iorio M, Vingiani A, Pruneri G, Verderio P. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. Front Oncol 2023; 12:1028825.
31.01.2023End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
31.01.2023Front Oncol 2023; 12:1028825
Di Cosimo Serena, Ciniselli Chiara M, Pizzamiglio Sara, Cappelletti Vera, Silvestri Marco, El-Abed Sarra, Izquierdo Miguel, Bajji Mohammed, Nuciforo Paolo, Huober Jens, Cameron David, Chia Stephen, Gomez Henry L, Iorio Marilena V, Vingiani Andrea, Pruneri Giancarlo, Verderio Paolo
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Núñez N, Berner F, Friebel E, Unger S, Wyss N, Gomez J, Purde M, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou M, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto P, Dummer R, Jäger E, Driessen C, Levesque M, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y) 2023
13.01.2023Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
13.01.2023Med (N Y) 2023
Núñez Nicolás Gonzalo, Berner Fiamma, Friebel Ekaterina, Unger Susanne, Wyss Nina, Gomez Julia Martinez, Purde Mette-Triin, Niederer Rebekka, Porsch Maximilian, Lichtensteiger Christa, Kramer Rafaela, Erdmann Michael, Schmitt Christina, Heinzerling Lucie, Abdou Marie-Therese, Karbach Julia, Schadendorf Dirk, Zimmer Lisa, Ugurel Selma, Klümper Niklas, Hölzel Michael, Power Laura, Kreutmair Stefanie, Capone Mariaelena, Madonna Gabriele, Cevhertas Lacin, Heider Anja, Amaral Teresa, Hasan Ali Omar, Bomze David, Dimitriou Florentia, Diem Stefan, Ascierto Paolo Antonio, Dummer Reinhard, Jäger Elke, Driessen Christoph, Levesque Mitchell Paul, van de Veen Willem, Joerger Markus, Früh Martin, Becher Burkhard, Flatz Lukas
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Nuciforo P, Townend J, Piccart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia A, Gomez H, Gombos A, Coccia-Portugal M, Tseng L, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer 2022; 181:92-101.
27.12.2022Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
27.12.2022Eur J Cancer 2022; 181:92-101
Nuciforo Paolo, Townend John, Piccart Martine, Fielding Shona, Gkolfi Panagiota, El-Abed Sarra, de Azambuja Evandro, Werutsky Gustavo, Bliss Judith, Moebus Volker, Colleoni Marco, Aspitia Alvaro Moreno, Gomez Henry, Gombos Andrea, Coccia-Portugal Maria Antonia, Tseng Ling-Ming, Kunz Georg, Lerzo Guillermo, Sohn Joohyuk, Semiglazov Vladimir, Saura Cristina, Kroep Judith, Ferro Antonella, Cameron David, Gelber Richard D, Huober Jens, Di Cosimo Serena
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Christiansen A, Lobo J, Fankhauser C, Rothermundt C, Cathomas R, Batavia A, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence. Front Oncol 2022; 12:1056823.
08.12.2022Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
08.12.2022Front Oncol 2022; 12:1056823
Christiansen Ailsa J, Lobo João, Fankhauser Christian D, Rothermundt Christian, Cathomas Richard, Batavia Aashil A, Grogg Josias B, Templeton Arnoud J, Hirschi-Blickenstorfer Anita, Lorch Anja, Gillessen Silke, Moch Holger, Beyer Jörg, Hermanns Thomas
Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer.
Koster K, Zumstein V, Süveg K, Jochum W, Husarik D, Omlin A. Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer. BJU Int 2022
05.12.2022Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer.
05.12.2022BJU Int 2022
Koster Kira-Lee, Zumstein Valentin, Süveg Krisztian, Jochum Wolfram, Husarik Daniela, Omlin Aurelius
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston S, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang C, Huober J, Jaliffe G, Cicin I, Tolaney S, Goetz M, Rugo H, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, Andre V, Harbeck N, Martín M. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2022
05.12.2022Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
05.12.2022Lancet Oncol 2022
Johnston Stephen R D, Toi Masakazu, O'Shaughnessy Joyce, Rastogi Priya, Campone Mario, Neven Patrick, Huang Chiun-Sheng, Huober Jens, Jaliffe Georgina Garnica, Cicin Irfan, Tolaney Sara M, Goetz Matthew P, Rugo Hope S, Senkus Elzbieta, Testa Laura, Del Mastro Lucia, Shimizu Chikako, Wei Ran, Shahir Ashwin, Munoz Maria, San Antonio Belen, Andre Valerie, Harbeck Nadia, Martín Miguel
Der Mystiker aus Nazaret
Renz M. Der Mystiker aus Nazaret - Jesuanische Spiritualität. Basel: Herder, 2022. ISBN 978-3-451-06875-1.
01.12.2022Der Mystiker aus Nazaret
01.12.2022Herder, ISBN 978-3-451-06875-1
Renz Monika
Von-Hippel-Lindau-Erkrankung
Koster K, Rothermundt C, Binet F, Borovicka J, Bozinov O, Clerici T, Engeler D, Greiner J, Hader C, Heinimann K, Azzarello-Burri S, Lang C, Krull I, Stöckli S, Omlin A, Hundsberger T. Von-Hippel-Lindau-Erkrankung - Interdisziplinäre Betreuung und neue therapeutische Optionen. Swiss Med Forum 2022; 48:4-784-787.
30.11.2022Von-Hippel-Lindau-Erkrankung
30.11.2022Swiss Med Forum 2022; 48:4-784-787
Koster Kira-Lee, Rothermundt Christian, Binet Françoise-Isabelle, Borovicka Jan, Bozinov Oliver, Clerici Thomas, Engeler Daniel S, Greiner J, Hader Claudia, Heinimann Karl, Azzarello-Burri Silvia, Lang Corina, Krull Ina, Stöckli Sandro, Omlin Aurelius, Hundsberger Thomas
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L. Return of individual genomic research results within the PRAEGNANT multicenter registry study. Breast Cancer Res Treat 2022
21.11.2022Return of individual genomic research results within the PRAEGNANT multicenter registry study.
21.11.2022Breast Cancer Res Treat 2022
Huebner Hanna, Ruebner Matthias, Kurbacher Christian, Hadji Peyman, Hartkopf Andreas D, Lux Michael P, Huober Jens, Uhrig Sabrina, Taran Florin-Andrei, Overkamp Friedrich, Tesch Hans, Häberle Lothar, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Hein Alexander, Belleville Erik, Untch Michael, Janni Wolfgang, Fehm Tanja N, Kolberg Hans-Christian, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Ettl Johannes, Fasching Peter A, Michel Laura L
Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.
Rothermundt C, Andreou D, Blay J, Brodowicz T, Desar I, Dileo P, Gelderblom H, Haas R, Jakob J, Jones R, Judson I, Kunz W, Liegl-Atzwanger B, Lindner L, Messiou C, Miah A, Reichardt P, Szkandera J, van der Graaf W, van Houdt W, Wardelmann E, Hofer S. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. Eur J Cancer 2022; 180:158-179.
16.11.2022Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.
16.11.2022Eur J Cancer 2022; 180:158-179
Rothermundt Christian, Andreou Dimosthenis, Blay Jean-Yves, Brodowicz Thomas, Desar Ingrid M E, Dileo Palma, Gelderblom Hans, Haas Rick, Jakob Jens, Jones Robin L, Judson Ian, Kunz Wolfgang G, Liegl-Atzwanger Berndadette, Lindner Lars H, Messiou Christina, Miah Aisha, Reichardt Peter, Szkandera Joanna, van der Graaf Winette T A, van Houdt Winan J, Wardelmann Eva, Hofer Silvia
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus 2022
12.11.2022Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
12.11.2022Eur Urol Focus 2022
Neuenschwander Anne, Lonati Chiara, Antonelli Luca, Papachristofilou Alexandros, Cathomas Richard, Rothermundt Christian, Templeton Arnoud J, Gulamhusein Aziz, Fischer Stefanie, Gillessen Silke, Hermanns Thomas, Lorch Anja, Mattei Agostino, Fankhauser Christian D
Mind-Body Online-Therapie im somatischen Setting – Entwicklung einer Online-Intervention im Rahmen der onkologischen Gynäkologie
Hämmerli Keller K, Markus A, Berger T, Huober J, Bekes I, Schmidt R, Gysin C, Schönenberger M, Germann N, Bürgin M, Diethelm S, Schmid D (2022). Mind-Body Online-Therapie im somatischen Setting – Entwicklung einer Online-Intervention im Rahmen der onkologischen Gynäkologie.
10.11.2022Mind-Body Online-Therapie im somatischen Setting – Entwicklung einer Online-Intervention im Rahmen der onkologischen Gynäkologie
10.11.2022Posterpräsentationen am den folgenden Kongressen: SAPPM SPS 2022 (Bern), SGPP 2022 (Bern)
Hämmerli Keller Katja, Markus Alexander, Berger Thomas, Huober Jens, Bekes Inga, Schmidt Roger, Gysin Christian, Schönenberger Michelle, Germann Nicolas, Bürgin Michelle, Diethelm Sarah, Schmid Dagmar
Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports.
Neff D, Padberg Sgier B, Dietze H, Müller J, Früh M. Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports. Case Rep Oncol 2022; 15:1001-1008.
08.11.2022Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports.
08.11.2022Case Rep Oncol 2022; 15:1001-1008
Neff Dominik, Padberg Sgier Barbara-Christina, Dietze Hannah, Müller Joachim, Früh Martin
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma.
Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau J, Jean D, Felley-Bosco E. Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. JTO Clin Res Rep 2022; 3:100430.
07.11.2022Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma.
07.11.2022JTO Clin Res Rep 2022; 3:100430
Sun Suna, Qi Weihong, Rehrauer Hubert, Ronner Manuel, Hariharan Ananya, Wipplinger Martin, Meiller Clément, Stahel Rolf, Früh Martin, Cerciello Ferdinando, Fonteneau Jean-François, Jean Didier, Felley-Bosco Emanuela